EVENTIDE ASSET MANAGEMENT, LLC - Significant Ownership

Signature - Title
Charlyne Devens - Investment Compliance Director
Location
Boston, MA
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by EVENTIDE ASSET MANAGEMENT, LLC.

Significant Ownership of EVENTIDE ASSET MANAGEMENT, LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BBNX Beta Bionics, Inc. Common Stock 11.32% $73M 4.86M Eventide Asset Management, LLC Jan 31, 2025
AURA Aura Biosciences, Inc. Common Stock, $0.00001 par value per share 8.17% $29.6M 4.08M Eventide Asset Management, LLC Dec 31, 2024
XMTR Xometry, Inc. Class A Common Stock, par value $0.000001 per share 6.72% $80.8M 3.15M Eventide Asset Management, LLC Dec 31, 2024
ZNTL Zentalis Pharmaceuticals, Inc. Common Stock, $0.001 par value per share 6.28% $9.04M 4.48M Eventide Asset Management, LLC Dec 31, 2024
MIRM Mirum Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share 5.43% $117M 2.61M Eventide Asset Management, LLC Dec 31, 2024
LXEO Lexeo Therapeutics, Inc. Common Stock, $0.0001 par value per share 3.73% $3.28M 1.23M Eventide Asset Management, LLC Dec 31, 2024
NKTR Nektar Therapeutics Common Stock, $0.0001 par value 3.61% $5.45M 6.65M Eventide Asset Management, LLC Dec 31, 2024
INZY Inozyme Pharma, Inc. Common Stock, par value $0.0001 per share 3.46% $2.35M 2.22M Eventide Asset Management, LLC Dec 31, 2024

Schedules 13D/G Reported by EVENTIDE ASSET MANAGEMENT, LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.